ICP-B03 / InnoCare - LARVOL DELTA

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 (PRNewswire) - “ICP-189: It is being developed for the treatment of solid tumors as a single agent and/or in combinations with other anti-tumor agents. We plan to submit the IND application for ICP-189 to the CDE in the second half of 2021; ICP-033: ICP-033 is intended to be used in combination with immunotherapy and other targeted therapy drugs for liver cancer, renal cell carcinoma, colorectal cancer and other solid tumors. We expect to file the IND application for ICP-033 in the first half of 2021; ICP-248: We intend to develop ICP-248 in combination with Orelabrutinib for the treatment of AML, ALL, FL, CLL, DLBCL and other hematological malignancies. We expect to file the IND application for ICP-248 in the first half of 2022; ICP-B03 – a tumor-conditional pro-interleukin (IL) – 15 targeting…We plan to apply for the IND application for ICP-B03 in the second half of 2022.”

IND • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor